LAGUNA BEACH, California, January 11 /PRNewswire/ -- Advanced Cardiac Therapeutics, Inc. ("ACT"), a developer of advanced irrigated cardiac ablation systems, announced today that it has completed a $5 million 'Series B' equity financing. The financing was led by NBGI Ventures, a venture capital firm specialized in medical technology investments, and is expected to fund commercialisation in Europe.
ACT was founded in 2007 to develop a novel irrigated radiofrequency cardiac ablation catheter with a diagnostic application of established microwave radiometry technology in association with the founder of the technology, Dr Kenneth Carr, and an experienced catheter development partner, Contract Medical International, based in Dresden, Germany.
Cardiac catheter ablation procedures are used to treat a variety of cardiac arrhythmias including Atrial Fibrillation (AF), which is estimated to affect over five million people in the USA and Europe. The procedures involve advancing a catheter into the heart and selectively ablating certain areas of tissue in order to prevent the spread of electrical signals that give rise to the arrhythmia. Most catheter ablation procedures are now conducted with irrigated catheters, in which saline is pumped through the tip during the application of energy, in order to prevent the tip from overheating and increasing risk of blood clotting events. However, as the tip is cooled, it is not possible to estimate the effect of the energy on the tissue by measuring the temperature at the surface of the tissue. ACT's technology will enable for the first time measurement of tissue temperature with an irrigated catheter. This will permit Electro-Physiologists greater control in their lesion creation and has the potential to improve patient outcomes.
"Unlike any other catheter today, ACT's technology allows the
Electro-Physiologist to optimize irrigated catheter generated
|SOURCE Advanced Cardiac Therapeutics|
Copyright©2010 PR Newswire.
All rights reserved